Stock AnalizSELLAS Life Sciences Group, Inc. SLS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
SELLAS Life Sciences Group, Inc. (SLS) is a healthcare company listed in the US with a market value of about $1.6B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -296%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1M | $8M | $2M | $0 | — | — | — |
| Net income | -$27M | -$31M | -$37M | -$41M | -$21M | -$17M | -$19M | -$28M | -$24M | -$18M |
| Free cash flow | — | — | — | — | — | — | — | — | — | -$12M |
| EPS (diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | $-10.92 | $-157.72 | $-522.00 | $-933.00 |
| Net margin | — | — | — | -4130.1% | -272.4% | -881.9% | — | — | — | — |
| ROIC | -39.3% | -301.1% | — | -723.8% | -118.2% | -58.6% | -316.3% | — | -139.4% | -74.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $32.50, 313% above the current price; targets range from $30.00 to $35.00; the consensus rating is “Strong buy”; expected EPS is $-0.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is SELLAS Life Sciences Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does SELLAS Life Sciences Group pay a dividend?
Not currently.
Is SELLAS Life Sciences Group a good stock to buy?
We do not give buy or sell advice. SELLAS Life Sciences Group scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.